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ABSTRACT  57 
Background:  58 
Patients with oesophago-gastric (OG) cancer may be at risk of malnutrition, troublesome 59 
gastrointestinal symptoms (GI) and reduced dietary intake in view of the tumour location and 60 
multimodality curative treatment approach. Longitudinal research is lacking. This study aimed to 61 
assess (1) nutritional status and how it evolved over the first year, (2) the association between 62 
nutritional status scores and GI symptom scores and (3) the nutrient and food group intake pattern. 63 
Methods: 64 
This was a prospective, observation study of patients with an OG lesion planned for radical treatment, 65 
with assessment at diagnosis, 3-months and 12-months following the start of treatment. Nutritional 66 
assessment was performed using the Patient-Generated Subjective Global Assessment (PG-SGA), GI 67 
symptoms measured using the modified Gastrointestinal Symptom Rating Scale and dietary intake 68 
assessed using a semi-quantitative food frequency approach. 69 
Results: 70 
 3 
80 patients (61 males, 19 females; aged 46-89y) were recruited. At baseline, 3 (n= 68) and 12 months 71 
(n= 57), 61%, 62% and 60% respectively were moderately/severely malnourished. Higher symptom 72 
burden was associated with poorer nutritional status at baseline (r= +0.55, p< 0.001), 3-months (r= 73 
+0.51, p< 0.001) and at 12-months (r= +0.42, p= 0.001). At each respective time point, 37%, 38% 74 
and 42% were meeting their Estimated Average Requirement for energy. No change in mean (SD) 75 
intake of energy, fibre, nutrient and food groups over time were observed. 76 
Conclusion:  77 
Patients with OG cancer have progressive weight loss, with malnutrition present in the majority 78 
during this year. Optimising nutritional status and symptom management throughout the treatment 79 
pathway should be a clinical priority.  80 
 81 
 82 
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 91 
INTRODUCTION  92 
Disease-related malnutrition occurs frequently in patients with cancer, with a high incidence in 93 
patients with oesophago-gastric (OG) cancer, ranging from 37-63% (1-3). The prevalence is 94 
dependent on tumour type and location, disease staging, treatment received and type of nutritional 95 
assessment method used (4,5). Most prevalence data is cross-sectional, not accounting for variations 96 
in nutritional status and malnutrition at different stages of treatment. The consequences of 97 
malnutrition in cancer are well recognised and include important adverse effects on clinical outcome 98 
e.g. increased risk of morbidity, decreased response and tolerance to treatment, decreased 99 
performance status and lower quality of life (6-10). 100 
 101 
It is likely that malnutrition and nutritional deterioration in OG cancer are caused by a dual 102 
mechanism, whereby negative local and systemic effects of the disease are compounded by acute and 103 
chronic nutrition-impact symptoms produced by treatments. Such treatment involves combinations 104 
of chemotherapeutic, radiotherapeutic and surgical regimens. A high burden of gastrointestinal (GI) 105 
 4 
symptoms is observed, although their co-occurrence and potential causal connection with 106 
malnutrition remains unclear (11-13). Likewise, inadequate oral intake may contribute to malnutrition 107 
in OG cancer but there are few studies assessing dietary intake, and those that do are very 108 
heterogeneous, use different dietary assessment methods and present conflicting results (14-16). 109 
Therefore, the contribution of inadequate oral intake to malnutrition in patients with OG cancer is 110 
uncertain. 111 
 112 
To date, the nutritional status, GI symptom burden or dietary intake of OG cancer patients has not 113 
been systematically measured longitudinally. This study aimed to (1) assess nutritional status and the 114 
prevalence of malnutrition at diagnosis and in the early (3 months, 3 m) and later stages (12 months, 115 
12 m) of treatment; (2) determine the association between GI symptom scores and nutritional status 116 
and malnutrition; and (3) assess nutrient and food group intake and its association with nutritional 117 
status and malnutrition.  118 
 119 
METHODS 120 
Subjects and Study Design  121 
A prospective, longitudinal cohort study of patients with a new oesophageal, gastro-oesophageal or 122 
gastric cancer (or pre-malignant disease of these locations) was conducted at a tertiary cancer centre 123 
in the United Kingdom, The Royal Marsden NHS Foundation Trust. Eligibility criteria were: 124 
cancer/pre-malignant disease confirmed by histopathology; planned to undergo radical treatment. 125 
Exclusion criteria were: age <18 years; receiving private healthcare; previous OG cancer; oncological 126 
treatment started >1 week before consent; unable to give informed consent.  127 
 128 
Each patient with a new OG cancer diagnosis was discussed at a weekly OG specialist multi-129 
disciplinary team meeting at the tertiary cancer centre. Here, a treatment plan was established for 130 
each individual and the study’s registered dietitian screened patients to identify those fulfilling the 131 
study’s inclusion criteria. Given the vulnerability of the patient group, the study dietitian liaised with 132 
other members of the multi-disciplinary team to determine the most appropriate time for her to 133 
approach eligible patients. This was often at one of their routine out-patient appointments with their 134 
oncologist or surgeon.  135 
 136 
Patients gave informed consent before study enrolment, with recruitment from 18th November 2011 137 
- 17th May 2013. The study visits were at diagnosis (before starting treatment) and at 3 m and 12 m 138 
after the treatment start date. Measurements of nutritional status, GI symptoms and dietary intake 139 
were taken by the same study dietitian at each time point. 140 
 5 
 141 
The study was reviewed and approved by the institutional clinical research and local ethics 142 
committees. The procedures followed were in accordance with the Helsinki Declaration of 1975 as 143 
revised in 1983. 144 
 145 
Nutritional Status 146 
Weights and heights were measured by the study dietitian using the Marsden M-120 Column Scales 147 
and the Marsden HM-200 Telescopic Height Measure respectively. The equipment was serviced and 148 
calibrated every six months by the equipment manufacturer. When measuring weight, the scales was 149 
positioned on a level surface, the patient removed their shoes and wore light day clothing (items in 150 
pockets and jewelry were removed). The presence of ascites and/or oedema was noted and where 151 
present, an estimated weight was recorded. 152 
 153 
Nutritional assessment was undertaken using the Patient Generated Subjective Global Assessment 154 
(PG-SGA) (17). It is the only validated and specific tool for a thorough nutritional assessment in 155 
oncology and has been accepted as the standard for nutrition assessment in oncology. 156 
 157 
The PG-SGA has two sections: a patient-completed component and a clinician component. The 158 
former has four parts (weight loss, nutrition impact symptoms, nutritional intake and functional 159 
capacity). The later also has four parts, which produces scores for diagnosis, age, metabolic stress, 160 
with a subjective physical examination assessing fat, muscle stores and fluid status. Finally, a global 161 
assessment of nutritional status is produced. 162 
 163 
The PG-SGA produces both subjective global ratings and a PG-SGA total score. The subjective 164 
global rating categories are consistent with the three categories from the Subjective Global 165 
Assessment (SGA) tool: PG-SGA-A (well-nourished), PG-SGA-B (moderately/suspected 166 
malnourished) and PG-SGA-C (severely malnourished). PG-SGA total scores range from 0-49, with 167 
triage recommendations as follows: score 0-1 (no intervention required); score 2-3 (patient and family 168 
education with pharmacological intervention and/or laboratory values); score 4-8 (requires 169 
intervention by dietitian in conjunction with nurse or physician); score ≥ 9 (critical need for improved 170 
symptom management and/or nutrient intervention options).  171 
 172 
For ethical reasons standard clinical practice was followed regarding dietary intervention in study 173 
patients. That is, members of the multidisciplinary team were able to refer patients to a separate 174 
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clinical dietitian based upon their own clinical opinion. The study dietitian would also refer patients 175 
to the clinical dietitian in those with a PG-SGA total score of ≥4. 176 
 177 
Gastrointestinal Symptoms 178 
Presence and severity of GI symptoms were measured using a modified version of the original 15-179 
symptom Gastrointestinal Symptom Rating Scale (GSRS) (18). The purpose of modification, was to 180 
increase the time over which the tool captures symptoms and to make it more disease-specific by 181 
adding relevant symptoms (dysphagia to fluids and/or solids, odynophagia to fluids and/or solids, 182 
early satiety, regurgitation of fluids and/or solids, faecal incontinence) and by removing symptoms 183 
considered irrelevant (hunger pains and sucking sensation in epigastrium). The modified tool 184 
measured 22 GI symptoms over the previous four weeks using a 4-point Likert scale (0= absent 185 
symptom; 1= mild symptom occurring occasionally but did not impact much; 2= moderate symptom 186 
occurring often and that impacted quite a bit; 3= severe symptom occurring a lot and that impacted a 187 
great deal). Individual scores were recorded for each GI symptom, and the sum of all 22 GI symptom 188 
scores was used to produce a GSRS total score (potential minimum score of 0 and maximum of 66). 189 
 190 
Dietary Intake 191 
The dietary assessment tool was the European Prospective Investigation into Cancer Food Frequency 192 
Questionnaire (FFQ) (Norfolk version). This is a semi-quantitative FFQ validated for assessing 193 
habitual dietary intake for the previous 12 months in the European Prospective Investigation into 194 
Cancer population (19-22). This FFQ contains a list of 130 foods items and a multiple response grid. 195 
Food lists and portion sizes are representative of an adult population in the United Kingdom following 196 
a traditional diet. Patients were requested to complete the FFQ based upon intake over the previous 197 
one month (rather than over the previous 12 months) so as to align with the study design. 198 
 199 
Data entry and analysis of the FFQs was undertaken using FETA software to produce nutrient and 200 
food group intake data (23). Data on intake of vitamin and micronutrient supplements, oral nutritional 201 
supplements and enteral nutrition were collected but could not be computed using FETA software. 202 
The data presented are for oral intake from food exclusively.   203 
 204 
Statistical Analysis 205 
As this was an observational study, with no group comparisons and no reporting of effect size, it was 206 
not necessary to power the study. A maximum recruitment period of 18 months was possible. No 207 
missing data was replaced. Statistical analyses were conducted using the Statistical Package for the 208 
Social Sciences software (version 22.0, IBM, USA). Paired continuous data were compared using 209 
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paired t-tests, with a 2-sided significance level of 5% used to assess significant difference between 210 
the data. The Kolmogorov-Smirnov test was used to examine the distribution of GSRS total scores 211 
and PG-SGA total scores, both of which were non-normally distributed. Median and range were used 212 
to summarise the data and the data were compared between different time points using non-parametric 213 
tests (Wilcoxon test). All other data were normally distributed.  214 
 215 
Change in patients’ PG-SGA category between baseline and 3 m and between baseline and 12 m were 216 
undertaken using cross-tabulation. 217 
 218 
The association between GI symptoms and nutritional status was measured in three ways. The 219 
association between overall GI symptoms (GSRS total scores) and nutritional status (PG-SGA total 220 
scores) were analysed using a Spearman’s rank correlation. Data were visualised using scatter plots 221 
and Dancey and Reidy’s categorisations aided the determination of the strength of the correlation 222 
using correlation co-efficients (r) (24). The nutritional status (PG-SGA total scores) of patients with 223 
(mild/moderate/severe) and without (absence) each of the GI symptoms was compared using a chi-224 
square test. Finally, a cross-tabulation was performed to compare those with presence (i.e. mild, 225 
moderate or severe) and absence of each GI symptom measured with respect to malnutrition category 226 
(PG-SGA A and PG-SGA B+C).  227 
 228 
Descriptive analysis was undertaken to report the FFQ data using mean (SD) intake of energy, 229 
macronutrients, micronutrients and fibre and 14 food groups. For those with three FFQs, repeated 230 
measures analysis of variance (ANOVA) compared the intakes at the three time points, and where p< 231 
0.05, a Bonferroni post-hoc test was performed to determine the differences between each time point. 232 
The proportion meeting their requirements at each study visit was calculated by comparison with the 233 
relevant Dietary Reference Value for energy (Estimated Average Requirement) and protein (25). 234 
 235 
RESULTS 236 
The participant flow chart is shown in the Figure contained in the supplementary material: 80 patients 237 
were recruited; 68 completed the 3 m assessment; 57 completed the 12 m assessment. The baseline 238 
characteristics and treatment details of the 61 (76%) males and 19 (24%) females are shown in Table 239 
1. A number of patients had at least one consultation with a clinical dietitian as either an in- or out-240 
patient in the three-month period before baseline (32, 40%), in the baseline to 3 m period (45, 66.2%) 241 
and in the 3 m to 12 m period (42, 73.7%). The mean (SD) number of consultations with the clinical 242 
dietitian per patient, for the respective periods was 1.6 (0.9), 3.2 (4.3) and 7.9 (7.4).  243 
 244 
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Nutritional Status  245 
The mean (SD) body weights at baseline (n= 80), 3 m (n= 68) and 12 m (n= 57) were: 76.6 (17.2) kg, 246 
74.4 (14.8) kg and 71.6 (16.7) kg respectively, with BMIs of 26.7 (4.7) kg/m2, 25.9 (4.1) kg/m2 and 247 
25.0 (4.9) kg/m2 respectively. Paired score comparisons were performed for those with data available 248 
at two (or more) time points, with significant reductions in weight and BMI as per the p-values: for 249 
baseline to 3 m they were 0.003 and 0.006 respectively; for baseline to 12 m and also for 3 m to 12 250 
m they were < 0.001 and < 0.001 respectively. Of the patients with all data points, n= 12 (21%) gained 251 
weight from baseline to 12 m, with a mean percentage weight gain of 6.1%. The remaining n= 45 252 
(79%) lost weight, with a mean percentage weight loss of 11.1% over the 12 m period.  253 
 254 
The scores from the components of PG-SGA are reported in Table A of the supplementary material. 255 
The proportion experiencing recent unintentional weight loss decreased from 57.5% at baseline to 256 
42.7% at 3 m and 26.3% at 12 m. For worksheet 4 (nutrition-related physical examination and 257 
anthropometric assessment), at least 30% of patients were found to have some depletion of fat and 258 
muscle stores (and/or the presence of ascites/oedema). The prevalence of moderate/suspected/severe 259 
malnutrition was 61.2% at baseline, 61.8% at 3 m and 59.6% at 12 m (Table 2). No significant 260 
difference in PG-SGA score between any time points was identified.  261 
 262 
Using the cross-tabulation method, it was noted that from baseline to 12 m (n= 57), 14 (24.6%) 263 
improved their nutritional status category, 16 (28%) worsened their category and 27 (47.4%) 264 
remained stable. Nineteen (33%) patients were moderately/severely malnourished at both diagnosis 265 
and 12 m (i.e. malnutrition ‘persisted’), while 15 (27%) were well-nourished at diagnosis but became 266 
moderately/severely malnourished by 12 m (i.e. malnutrition ‘developed’). 267 
 268 
Association Between Gastrointestinal Symptoms and Nutritional Status 269 
The median (range) GSRS total score at baseline (n= 80) was 12/66 (0-46), at 3 m (n= 68) was 9.5/66 270 
(0-39) and at 12 m (n= 57) was 12/66 (0-46). There was moderate correlation between GSRS total 271 
score and PG-SGA total score at baseline (r= +0.55, p< 0.001), 3 m (r= +0.51, p< 0.001) and 12 m 272 
(r= +0.42, p= 0.001). At baseline, there was a greater prevalence of moderate/severe malnutrition in 273 
patients with 11 individual GI symptoms (dysphagia to solids, dysphagia to fluids, odynophagia to 274 
solids, odynophagia to fluids, belching, nausea, early satiety, abdominal grumbling, hard stools, 275 
constipation, incomplete evacuation), at 3 m there was a greater prevalence for only three GI 276 
symptoms (early satiety, constipation, incomplete evacuation). There were no significant differences 277 
in prevalence of malnutrition between those with and without GI symptoms at 12 m (Table 3) 278 
 279 
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Dietary Intake 280 
At baseline, 3- and 12 m, 79/80 (98.8%), 62/68 (91.2%) and 53/57 (92.9%) were managing some oral 281 
intake respectively, with 18 (22.5%), 13 (20.9%) and 5 (9.4%) consuming foods with a modified 282 
texture. Of these, 3.8% at baseline, 58.1% at 3 m and 5.7% at 12 m had an oesophageal stent; while 283 
25.3%, 38.2% and 28.1% were prescribed oral nutritional supplements. There were 3/80 (3.8%), 7/68 284 
(10.2%), 6/57 (10.5%) enterally fed (either sole or supplementary nutrition source) at baseline, 3 m 285 
and 12 m, with only 1/68 (1.5%) at 3 m requiring parenteral nutrition support.  286 
 287 
78 FFQs were analysed at baseline, 61 at 3 m and 53 at 12 m. Of these patients, there were only 29 288 
(37.2%) at baseline, 23 (37.7%) at 3 m and 22 (41.5%) at 12 m meeting their Estimated Average 289 
Requirement for energy from food, though more were achieving their Dietary Reference Value for 290 
protein at baseline (62, 79.5%), 3 m (54, 88.5%) and 12 m (48, 90.6%). 43 patients completed a FFQ 291 
at all three visits and the mean energy and protein intake per kg/day were as follows: 29.9 kcal/kg 292 
and 1.3 g/kg at baseline; 30.5 kcal/kg and 1.2g/kg at 3 m; 31.9 kcal/kg and 1.3g/kg at 12 m. Results 293 
for the comparison of daily energy, fibre, nutrient and food group intakes at each visit are shown in 294 
Table B of supplementary material. There was no significant change in the intake of any of the 295 
variables over time following Bonferroni post-hoc testing, where relevant.  296 
 297 
DISCUSSION 298 
 299 
This is the first study to record systematically nutritional status using a validated assessment method 300 
in OG cancer during the first year following diagnosis. Cancers of the GI tract are known to exert 301 
higher nutritional risk than other cancer sites (1,3,26). Heburterne et al.’s prevalence study indicated 302 
that patients with OG cancer had the second highest prevalence of malnutrition (60%) after pancreatic 303 
cancer. This supports earlier work where 61% of newly diagnosed OG cancer patients were shown to 304 
have > 5% unintentional weight loss (1). In the current study the prevalence of malnutrition was found 305 
to be 61% at baseline, and this value remained unchanged over time.  306 
 307 
Although the overall values for malnutrition prevalence remained stable, this reflects a dynamic 308 
process of improvement, deterioration, and maintenance in different patients. Of those who were 309 
malnourished at baseline, this persisted until 12 m in one third, whilst of those who were well-310 
nourished at baseline, one quarter developed malnutrition by 12 m, meaning that malnutrition 311 
persisted or developed in the majority. 312 
 313 
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While, we were already aware that gastrointestinal (GI) symptoms are observed in OG cancer patients 314 
(11-13), until now, we were unclear about their co-occurrence with malnutrition. Our results 315 
demonstrate moderate correlation between symptom and nutritional status scores throughout this first 316 
year. Importantly, we now have specific GI symptoms (in particular dysphagia, odynophagia, nausea, 317 
abdominal pain and early satiety) that we know to be associated with poorer nutritional status (Table 318 
3). We know that by 12 m, most study patients no longer had cancer, so we suspect that their poor 319 
nutritional status had less to do with the primary effect of the cancer (i.e. imbalance between pro- and 320 
anti-inflammatory cytokines and abnormalities in substrate metabolism) and more to do with GI 321 
symptom burden. 322 
 323 
Our study provides strength to the argument that the multidisciplinary approach towards treatment 324 
decisions should also be expanded to include much more active assessment and management of acute 325 
and chronic GI symptoms, to prevent them from negatively affecting nutritional status (27).  326 
Likewise, inadequate oral intake may contribute to malnutrition in OG cancer but there are few 327 
studies assessing dietary intake in these patients. As per the 2017 ESPEN guidelines on nutrition in 328 
cancer patients, 25-30 kcal/kg/day and 1.2-1.5 g protein/kg/day can serve as a target ranges to help 329 
maintain or restore lean body mass, where individual measurements are unavailable (28). Results 330 
from this study suggest that inadequate oral intake is, indeed, likely to be playing a role in their 331 
malnutrition.   332 
 333 
Although mean energy intake appeared adequate (30-32kcal/kg/day) to meet the ESPEN target, we 334 
note that less than half were meeting their Estimated Average Requirement for energy from food 335 
during the year. Similarly, while 80-90% were meeting their Dietary Reference Value for protein, 336 
with intakes of 1.2-1.3g/kg/day, ESPEN suggest that protein intakes should, if possible, reach 1.5 337 
g/kg/day, especially where muscle depletion is present, as was the case in one-third of this cohort.  338 
 339 
Considering these findings, and given that there was no increase in energy or protein intakes during 340 
the course of the study, we suggest that the chronic energy and protein deficits contributed, at least 341 
in part, to the ongoing weight loss observed. These data are concerning, considering that, following 342 
the commencement of treatment, the majority had at least one consultation with a clinical dietitian 343 
and many were taking oral nutritional supplements. This questions the effectiveness of current 344 
interventions (predominately food fortification advice and oral nutritional supplementation), and 345 
suggests that earlier and more intensive input (i.e. enteral support) may be necessary to prevent 346 
nutritional decline.  347 
 348 
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Best practice guidelines advocate for early identification and commencement of nutrition intervention 349 
to maintain quality of life (1,29,30). Also, the nutritional benefits of an early and intensive 350 
intervention (weekly dietetic consultations for 18 weeks) in OG cancer was demonstrated in a pilot 351 
study (31), with weight 6 kg greater and PG-SGA score 10 points lower in the intervention group 352 
compared with standard care group. Larger, well-conducted RCTs are required to better understand 353 
the effectiveness of intensive interventions.  354 
 355 
Strengths and limitations 356 
The decision to include patients with Barrett’s oesophagus or a pre-malignancy may represent a 357 
limitation of this study considering these patients do not usually have dysphagia or weight loss at 358 
presentation. However, this should not materially affect the results as these patients were so few (n= 359 
4). Also of note, the groups of patients were not evenly distributed, as the majority were men. Many 360 
of the assessment methods relied, to varying extents, on recall, and therefore may be prone to recall 361 
bias.  362 
 363 
Another weakness relates to the FFQ, which significantly overestimates energy and fibre intake, as 364 
well as many macro- and micronutrients when compared with weighed records (19). This means that 365 
caution should be used in applying the estimates of individual diets. In addition, the Dietary Reference 366 
Values provide a guide to the adequacy of dietary intake among healthy populations and therefore do 367 
not necessarily reflect the requirements of patients with cancer (32). Therefore, interpretation of the 368 
FFQ data must be done with caution. 369 
 370 
This study’s strength lies in its longitudinal design, which is atypical in cancer research concerned 371 
with nutrition, as the majority of data comes from cross-sectional studies. By following the course of 372 
nutritional status, dietary intake and GI symptoms over one year, these results highlight the 373 
importance of the comprehensive assessment from diagnosis, acutely during treatment and 374 
chronically. Attrition due to the death is inevitable in the context of longitudinal research in cancer 375 
patients and accounted for 18%. But the withdrawal and loss to follow-up rate was low at 11%. 376 
Neither inter-investigator bias nor non-random sampling are relevant here as one researcher 377 
completed all assessment and the recruited and declined populations were comparable (data not 378 
presented). 379 
 380 
In conclusion, those with OG cancer experience a progressive weight loss over time and malnutrition 381 
is present in the majority during the first year. Current detection and treatment processes appearing 382 
sub-optimal. Optimising nutritional status throughout the treatment pathway should be considered a 383 
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priority in this high-risk group. We suggest an intensive approach, which might include weekly 384 
nutritional assessment during oncological treatments, and follow-up after their completion until no 385 
further risk exists. Ongoing assessment of GI function can be incorporated into the dietitian’s 386 
assessments, as well as other relevant health care providers. As this work has demonstrated that 387 
symptom burden showed an association with nutritional status, whereby the presence of symptoms 388 
tended to be associated with poorer nutritional status and vice versa, it seems reasonable to 389 
hypothesize that the effective treatment of GI symptoms that are negatively impacting on dietary 390 
intake would improve nutritional status. 391 
 392 
 393 
 394 
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References 
1. Baldwin C, McGough C, Norman AR, Frost GS, Cunningham DC, Andreyev 
HJN. Failure of dietetic referral in patients with gastrointestinal cancer and 
weight loss. Eur J Cancer 2006;42:2504–9.  
2. Bozzetti F, Mariani L, Vullo LoS, SCRINIO Working Group, Amerio ML, 
Biffi R et al. The nutritional risk in oncology: a study of 1,453 cancer 
outpatients. Support Care Cancer 2012;20:1919–28.  
3. Hebuterne X, Lemarie E, Michallet M, de Montreuil CB, Schneider SM, 
Goldwasser F. Prevalence of malnutrition and current use of nutrition support 
in patients with cancer. JPEN 2014;38:196–204.  
4. Shike M. Nutrition therapy for the cancer patient. Hematol Oncol Clin of North 
Am 1996;10:221–34.  
5. Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P. Malnutrition 
after oesophageal cancer surgery in Sweden. Br J Surg 2007;94:1496–500.  
6. Ottery FDF. Definition of standardized nutritional assessment and 
interventional pathways in oncology. Nutrition 1996;12:S15–9.  
7. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with 
weight loss have a worse outcome when undergoing chemotherapy for 
gastrointestinal malignancies? Eur J Cancer 1998;34:503–9.  
8. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR et al. 
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J 
Med 1980;69:491–7.  
9. van Cutsem E, Arends J. The causes and consequences of cancer-associated 
malnutrition. Eur J Oncol Nurs 2005;9 Suppl 2:S51–63.  
10. Kyle UG, Pirlich M, Lochs H, Schuetz T, Pichard C. Increased length of 
hospital stay in underweight and overweight patients at hospital admission: a 
controlled population study. Clin Nutr 2005;24:133–42.  
11. Sánchez-Lara K, Ugalde-Morales E, Motola-Kuba D, Green D. 
 14 
Gastrointestinal symptoms and weight loss in cancer patients receiving 
chemotherapy. Br J Nutr 2012;109:894–7.  
12. Bovio G, Montagna G, Bariani C, Baiardi P. Upper gastrointestinal symptoms 
in patients with advanced cancer: relationship to nutritional and performance 
status. Support Care Cancer 2009;17:1317–24.  
13. Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR et al. 
Symptoms and weight loss in patients with gastrointestinal and lung cancer at 
presentation. Support Care Cancer 2007;15:39–46.  
14. Bae JM, Park JW, Yang HK, Kim JP. Nutritional status of gastric cancer 
patients after total gastrectomy. World J Surg 1998;22:254–60.  
15. Ludwig DJ, Thirlby RC, Low DE. A prospective evaluation of dietary status 
and symptoms after near-total esophagectomy without gastric emptying 
procedure. Am J Surg 2001;181:454–8.  
16. Carey S, Storey D, Biankin AV, Martin D, Young J, Allman-Farinelli M. Long 
term nutritional status and quality of life following major upper gastrointestinal 
surgery - A cross-sectional study. Clin Nutr 2011;30:774–9.  
17. Ottery FD. Nutrition Screening and Assessment in Oncology. In: McCallum P, 
Polisena C, eds. The clinical guide to oncology nutrition. Chicago: American 
Dietetic Association, 2000 11–23.  
18. Svedlund J, Sjödin I, Dotevall G. GSRS—a clinical rating scale for 
gastrointestinal symptoms in patients with irritable bowel syndrome and peptic 
ulcer disease. Dig Dis Sci 1988;33:129–34.  
19. Bingham S. Validation of dietary assessment methods in the UK arm of EPIC 
using weighed records, and 24-hour urinary nitrogen and potassium and serum 
vitamin C and carotenoids as biomarkers. Int J Epidemiol 1997;26:S137–51.  
20. McKeown NM, Day NE, Welch AA, Runswick SA, Luben RN, Mulligan AA 
et al. Use of biological markers to validate self-reported dietary intake in a 
random sample of the European Prospective Investigation into Cancer United 
 15 
Kingdom Norfolk cohort. Am J Nutr 2001;74:188–96.  
21. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J et al. 
Reproducibility and validity of a semiquantitative food frequency 
questionnaire. Am J Epidemiol 1985;122:51–65.  
22. Willett WC, Sampson L, Browne ML, Stampfer MJ, Rosner B, Hennekens CH 
et al. The use of a self-administered questionnaire to assess diet four years in 
the past. Am J Epidemiol 1988;127:188–99.  
23.    Mulligan AA, Luben RN, Bhaniani A, Parry-Smith DJ, O'Connor L, Khawaja 
AP et al. A new tool for converting food frequency questionnaire data into 
nutrient and food group values: FETA research methods and availability. BMJ 
2014;4:1–12. 
24. Dancey CP, Reidy J. Chapter 5. In: Dancey CP, Reidy J, eds. Statistics Without 
Maths for Psychology: using SPSS for Windows. 3rd ed. Essex: Pearson 
Education, 2004 163-205.  
25. Scientific Advisory Committee on Nutrition. Dietary Reference Values for 
Energy. London: Stationery Office/TSO, 2012.  
26. Koom WS, Ahn SD, Song SY, Lee CG, Moon SH, Chie EK et al. Nutritional 
status of patients treated with radiotherapy as determined by subjective global 
assessment. Radiat Oncol J 2012;30:132.  
27. Grover S, Lim RM, Blumberg RS, Syngal S. Oncogastroenterology. J Clin 
Oncol 2016;34:1154–5.   
28.  Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F et al. 
ESPEN  guidelines on nutrition in cancer patients. Clin Nutr 2017;36:11–48. 
 
 
29. Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with 
cancer cachexia receiving chemotherapy? A pilot study. Support Care Cancer 
2005;13:270–4.  
30. Ottery FD. Cancer cachexia: prevention, early diagnosis, and management. 
 16 
Cancer Pract 1994;2:123–31.  
31. Silvers MA, Savva J, Huggins CE, Truby H, Haines T. Potential benefits of 
early nutritional intervention in adults with upper gastrointestinal cancer: a 
pilot randomised trial. Support Care Cancer 2014;22:3035–44.   
32. Committee on Medical Aspects of Food Policy (Department of Health, ed). 
Dietary Reference for Food Energy and Nutrients for the United Kingdom. 
London: Stationery Office/TSO, 1991.  
Table 1: Baseline characteristics and treatment details of the recruited cohort1 
Baseline characteristics Males 
 (n= 61) 
Females  
(n= 19) 
Age (y), median (min-max) 66 (47-89) 61 (46-80) 
Eastern Cooperative Oncology Group performance status 
    0 25 (41) 10 (52.6) 
    1 31 (50.8) 8 (42.1) 
    2 4 (6.6) 1 (5.3) 
    3 1 (1.6) 0 (0) 
    4 0 (0) 0 (0) 
Current diagnosis 
    AC of upper and middle third of oesophagus  21 (34.4) 2 (10.5) 
    AC of lower third of oesophagus, Siewert type I 12 (19.7) 2 (10.5) 
    SCC of the oesophagus 8 (13.1) 4 (21.1) 
    Siewert type II and III  3 (4.9) 3 (15.8) 
    AC of stomach  11 (18) 4 (21.1) 
    Gastrointestinal stromal tumour of the stomach 2 (3.3) 3 (15.8) 
    Barrett’s oesophagus  1 (1.6) 0 (0) 
    Other malignant/premalignant neoplasm 3 (4.9) 1 (5.3) 
Histopathological tumour (T) staging 
     0-1  5 (8.2) 1 (5.3) 
     2 9 (14.8) 5 (26.3) 
     3 41 (67.2) 7 (36.8) 
     4  4 (6.6) 1 (5.3) 
    Not applicable  2 (3.2) 5 (26.3) 
Undergoing active oncological treatment 
      At 3 m (n= 68)   
      At 12 m (n= 57)   
Treatment modalities received up to 12 m (n= 57) 
     Surgery alone 3 (5.3)   
     Surgery and chemotherapy 32 (56.1)   
     Surgery, chemotherapy and radiotherapy 7 (12.3)   
     Chemotherapy and radiotherapy 13 (22.8)   
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     Chemotherapy alone 2 (3.5)   
1All values are expressed as counts (%) unless otherwise stated. Baseline characteristics are 
reported for the 80 patients at initial visit (n= 61 males, n=19 females). Treatment details are 
reported for the number of patients in parentheses. 
AC, adenocarcinoma; SCC, squamous cell carcinoma 
 
 
 
Table 2 Patient-Generated Subjective Global Assessment total scores and categories 1 
 Baseline  
(n= 80) 
3 month  
(n= 68) 
12 month 
(n= 57) 
 
PG-SGA total score 9 (0-28) 6 (2-26) 7 (0-19) 
 
PG-SGA category scores  
A: Well-nourished 31 (38.8) 26 (38.2) 23 (40.4) 
 
B: Moderately/suspected malnourished 47 (58.7) 40 (58.8) 32 (56.1) 
 
C: Severely malnourished 
 
 
Total: B + C  
 
 
2 (2.5) 
 
 
49 (61.2) 
 
 
2 (3) 
 
 
42 (61.8) 
 
 
2 (3.5) 
 
 
34 (59.6) 
 
 
1 PG-SGA total score is expressed as median (min-max). PG-SGA category scores are expressed as 
counts (%). PG-SGA, Patient Generated Subjective Global Assessment. 
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Table 3 Association between the presence of gastrointestinal symptoms (mild, moderate or 
severe) and Patient-Generated Subjective Global Assessment category  
 
Baseline n= 80  
PG-SGA, n (%) 
3 m n= 68 
PG-SGA, n (%) 
12 m n= 57 
PG-SGA, n (%) 
A B+C p-
value 
A B+C p-
value 
A B+C p-
value 
Dysphagia 
to solids 
11 
(23.4) 
36 
(76.6) 
0.001 
** 
6 (24) 19 (76) 0.055 7 (33.3) 14 
(66.7) 
0.294 
Dysphagia 
to fluids 
5 (19.2) 21 
(80.8) 
0.011 
* 
4 (25) 12 (75) 0.171 3 (27.3) 8 (72.7) 0.264 
Odynophagi
a to solids 
9 (26.5) 25 
(73.5) 
0.030 
* 
4 (26.7) 11 
(73.3) 
0.231 2 (22.2) 7 (77.8) 0.204 
Odynophagi
a to fluids 
3 (15) 17 (85) 0.009 
** 
1 (16.7) 5 (83.3) 0.240 0 (0) 4 (100) 0.117 
Regurgitatio
n of solids 
9 (27.3) 24 
(72.7) 
0.062 3 (20) 12 (80) 0.087 6 (37.5) 10 
(62.5) 
0.514 
Regurgitatio
n of fluids 
7 (25.9) 20 
(74.1) 
0.074 2 (18.2) 9 (81.8) 0.122 6 (37.5) 10 
(62.5) 
0.514 
Heartburn 12 
(42.9) 
16 
(57.1) 
0.401 6 (35.3) 11 
(64.7) 
0.482 5 (33.3) 10 
(66.7) 
0.346 
Acid reflux 12 
(34.3) 
23 
(65.7) 
0.312 7 (30.4) 16 
(69.6) 
0.249 10 
(41.7) 
14 
(58.3) 
0.539 
Belching 15 (30) 35 (70) 0.033 
* 
17 
(47.2) 
19 
(52.8) 
0.085 13 
(35.1) 
24 
(64.9) 
0.209 
Nausea 3 (12) 22 (88) 0.001 
** 
14 
(37.8) 
23 
(62.2) 
0.569 8 (36.4) 14 
(63.6) 
0.419 
Early satiety 7 (18.4) 31 
(81.6) 
0.000 
*** 
8 (21.1) 30 
(78.9) 
0.001 
** 
7 (28) 18 (72) 0.079 
Bloating 8 (34.8) 15 
(65.2) 
0.420 
5 (29.4) 
12 
(70.6) 
0.285 9 (47.4) 10 
(52.6) 
0.315 
Abdominal 
grumbling 
10 (27) 27 (73) 0.038 
* 
16 
(42.1) 
22 
(57.9) 
0.314 14 
(37.8) 
23 
(62.2) 
0.402 
Abdominal 
pain 
13 
(37.1) 
22 
(62.9) 
0.489 7 (30.4) 16 
(69.6) 
0.249 12 
(35.3) 
22 
(64.7) 
0.251 
Flatulence 16 
(33.3) 
32 
(66.7) 
0.163 17 
(38.6) 
27 
(61.4) 
0.569 14 (35) 26 (65) 0.166 
Loose stools 10 
(43.5) 
13 
(56.5) 
0.380 12 
(41.4) 
17 
(58.6) 
0.449 10 
(30.3) 
23 
(69.7) 
0.062 
Diarrhoea 3 (20) 12 (80) 0.084 9 (32.1) 19 
(67.9) 
0.271 8 (30.8) 18 
(69.2) 
0.140 
Faecal 
urgency 
10 
(43.5) 
13 
(56.5) 
0.380 10 
(41.7) 
14 
(58.3) 
0.431 8 (29.6) 19 
(70.4) 
0.097 
Faecal 
incontinence 
3 (27.3) 8 (72.7) 0.299 5 (45.5) 6 (54.5) 0.414 5 (33.3) 10 
(66.7) 
0.669 
Hard stools 8 (22.9) 27 
(77.1) 
0.007 
** 
10 
(33.3) 
20 
(66.7) 
0.314 7 (31.8) 15 
(68.2) 
0.223 
Constipation 6 (16.7) 30 
(83.3) 
0.000 
*** 
8 (25) 24 (75) 0.030 
* 
10 
(43.5) 
13 
(56.5) 
0.451 
Incomplete 
evacuation 
8 (25) 24 (75) 0.033 
* 
6 (21.4) 22 
(78.6) 
0.015 
* 
10 
(38.5) 
16 
(61.5) 
0.503 
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Supplementary Table A Patient-Generated Subjective Global Assessment total score 
components1 
 Baseline  
(n= 80) 
3 month  
(n= 68) 
12 month  
(n= 57) 
PG-SGA total score components  
Box 1: Weight 
0 (not changed/increased) 
1 (lost in past 2 weeks) 
2 
3 
4 
5 
 
34 (42.5) 
15 (18.7) 
10 (12.5) 
12 (15) 
6 (7.5) 
3 (3.8) 
 
39 (57.3) 
7 (10.3) 
6 (8.8) 
8 (11.8) 
7 (10.3) 
1 (1.5) 
 
42 (73.7) 
5 (8.8) 
3 (5.3) 
4 (7) 
3 (5.2) 
0 (0) 
Box 2: Food intake 
0   (same/more than usual) 
1   (less food than usual) 
2   (little solid food) 
3   (supplements only) 
4   (very little of anything) 
 
31 (38.8) 
29 (36.2) 
11 (13.7) 
9 (11.3) 
0 (0) 
 
35 (51.5) 
20 (29.4) 
11 (16.1) 
1 (1.5) 
1 (1.5) 
 
27 (47.4) 
24 (42.1) 
6 (10.5) 
0 (0) 
0 (0) 
Box 3: Symptoms 
0-3   (none/few symptoms) 
4-6   (several symptoms) 
7+    (many symptoms) 
 
43 (53.7) 
11 (13.8) 
26 (32.5) 
 
45 (66.2) 
13 (19.1) 
10 (14.7) 
 
35 (61.4) 
10 (17.5) 
12 (21.1) 
Box 4: Activities and function 
0   (no limitations) 
1   (not normal self) 
2   (not up to most things) 
3   (able for little activity) 
 
53 (66.2) 
18 (22.5) 
7 (8.8) 
2 (2.5) 
 
22 (32.4) 
26 (38.2) 
11 (16.2) 
9 (13.2) 
 
31 (54.4) 
15 (26.4) 
7 (12.2) 
4 (7) 
Sum of Boxes 1-4 
0-6 
7-12 
13-18 
19-24 
 
37 (46.3) 
28 (35) 
10 (12.4) 
5 (6.3) 
 
44 (64.7) 
14 (20.6) 
9 (13.2) 
1 (1.5) 
 
38 (66.7) 
14 (24.5) 
5 (8.8) 
0 (0) 
Worksheet 2: Relevant diagnoses 
0 (no diagnoses) 
1 (one diagnosis) 
2 (two diagnoses) 
3 (three diagnoses) 
 
2 (2.5) 
32 (40) 
46 (57.5) 
0 (0) 
 
0 (0) 
26 (38.2) 
41 (60.3) 
1 (1.5) 
 
3 (5.3) 
25 (43.9) 
28 (49.1) 
1 (1.7) 
Worksheet 3: Metabolic demand 
0 (no demand) 
1 (mild demand) 
 
80 (100) 
0 (0) 
 
67 (98.5) 
1 (1.5) 
 
57 (100) 
0 (0) 
3 m: 3 month; 12 m: 12 month. Pearson chi-square tests were undertaken to determine the association 
between individuals with/without a symptom and PG-SGA category A or category B+C. Fisher’s Exact 
tests were performed where expected cell count was less than 5. Data presented are for the 
association of the presence of a symptom and SGA B+C, where * p< 0.05; ** p< 0.01; *** p< 0.001. 
Data were incomplete as follows: Baseline; n= 79 for odynophagia to fluids, heartburn, faecal 
incontinence, hard stool; n= 78 for regurgitation of solids, loose stool; n= 76 for flatulence; n= 72 for 
constipation. 3-m; n= 67 for odynophagia to fluids, heartburn, loose stool. 12-m; n= 56 for heartburn.  
 
The higher the % lost in 
1- or 6 m, the higher the 
score. Add 1 if some lost 
in past 2 weeks 
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 Baseline  
(n= 80) 
3 month  
(n= 68) 
12 month  
(n= 57) 
Worksheet 4: Physical examination 
0 (no deficit) 
1 (mild deficit) 
2 (moderate deficit) 
3 (severe deficit) 
 
53 (66.2) 
19 (23.8) 
8 (10) 
0 (0) 
 
47 (69.1) 
15 (22.1) 
6 (8.8) 
0 (0) 
 
40 (70.2) 
11 (19.3) 
5 (8.8) 
1 (1.7) 
 
1 All values are expressed as counts (%) 
 
 
 
 
Supplementary Table B Comparison of daily intake of energy, fibre, nutrients and food 
groups from food1 
 Baseline 3 m 12 m 
    Energy, kcal/d 2253.1 (1179.5) 2222.1 (957.4) 2162.8 (834.6) 
    Protein, g/d 94.5 (46.1) 90.3 (42.8) 86.1 (29.8) 
    Carbohydrate, g/d 273.8 (157.7) 261.0 (110.4) 248.6(102.6) 
    Alcohol, g/d 7.9 (13.3) 3.7 (6.8) 5.7 (9.6) 
    Englyst Fibre, g/d 18.9 (12.5) 17.0 (8.9) 15.6 (7.8) 
    Vitamin A, μg/d 1936.5 (1149.1) 1997.6 (1827.2) 1730.4 (1204.4) 
    Vitamin B1, mg/d 1.7 (1.0) 1.6 (0.8) 1.5 (0.6) 
    Vitamin B2, mg/d 2.5 (1.2) 2.4 (1.1) 2.2 (1.0) 
    Vitamin B3, mg/d 24.4 (11.7) 23.0 (10.2) 22.0 (9.2) 
    Vitamin B6, mg/d 2.5 (1.2) 2.3 (1.1) 2.1 (0.8) 
    Vitamin B12, μg/d 9.1 (4.9) 9.2 (6.7) 8.3 (4.6) 
    Carotene, mg/d 4.3 (3.4) 4.1 (2.4) 3.3 (2) 
    Vitamin C, mg/d 131.1 (78.2) 130.5 (80.3) 113.6 (73.6) 
    Vitamin D, μg/d 3.7 (2.8) 3.8 (1.8) 3.6 (2.3) 
    Vitamin E, mg/d 14.3 (9.3) 13.2 (5.9) 12.8 (6.7) 
    Folate, μg/d 351.7 (178.5) 329.5 (168.5) 296.8 (129.7) 
    Calcium, mg/d 1181.1 (609.5) 1144.0 (542.1) 1058.3 (439.7) 
    Chloride, mg/d 4874.0 (2720.9) 4773.8 (1649.6) 4348.0 (1705.6) 
    Iron, g/d 12.6 (6.5) 11.3 (4.3) 11.2 (4.5) 
    Magnesium, mg/d 362.9 (182.3) 331.3 (169.1) 315.6 (123.5) 
    Phosphorus, mg/d 1665.7 (809.1) 1598.5 (673.8) 1511.3 (516.5) 
    Potassium, mg/d 4177.6 (1934.9) 3773.1 (1581.0) 3548.6 (1269.1) 
    Selenium, μg/d 72.3 (33.6) 69.5 (32.2) 63.6 (25.7) 
    Sodium, mg/d 3277.3 (1905.6) 3235.6 (1175.8) 2930.8 (1180.2) 
    Zinc, mg/d 10.8 (5.8) 10.3 (5.7) 9.8 (3.3) 
Food groups 
    Alcoholic beverages, g/d 138.9 (273.6) 70.0 (138.7) 106.9 (205.9) 
    Cereals, cereal products, g/d 270.1 (183.6) 257.9 (130.1) 246.3 (139.9) 
    Eggs, egg dishes, g/d 23.4 (25.2) 22.0 (14.8) 20.5 (22.8) 
    Fats, oils, g/d 28.0 (21.6) 30.7 (21.6) 30.4 (24.6) 
    Fish, fish products, g/d 49.2 (35.0) 46.6 (32.7) 43.1 (35.9) 
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 Baseline 3 m 12 m 
    Fruit, g/d 241.3 (261.9) 171.0 (184.0) 204.5 (210.8) 
    Meat, meat products, g/d 103.2 (65.4) 113.7 (82.3) 110.5 (63.5) 
    Milk, milk products, g/d 485.5 (272.7) 454.5 (206.3) 435.0 (225.9) 
    Non-alcoholic beverages, g/d 1032.5 (532.5) 932.4 (471.1) 817.5 (406.4) 
    Nuts, seeds, g/d 3.9 (6.4) 4.9 (8.3) 13.7 (30.2) 
    Potatoes, g/d 100.2 (61.5) 89.1 (50.2) 74.3 (48.8) 
    Soups, sauces, g/d 130.9 (157.1) 109.0 (93.9) 76.9 (67.5) 
    Sugars: preserves/snacks, g/d 63.5 (55.4) 64.2 (60.0) 65.7 (47.8) 
    Vegetables, g/d 319.9 (257.9) 284.0 (175.6) 238.2 (156.5) 
3 m: 3 month; 12 m: 12 month. 1 For all variables, results are expressed as average value/day. Results presented are for the 43 patients with FFQ data 
available at all 3 study visits. Vitamin A refers to retinol equivalents; carotene refers to total carotene equivalents. Analyzed by repeated measures ANOVA; 
Mauchly's Test of Sphericity was performed and Greenhouse-Geisser corrections were made if the data violated the assumption of sphericity. For 
nutrient/food groups with significantly different means across the three time points using ANOVA (alcohol, alcoholic beverages, nuts and seeds), a 
Bonferroni post-hoc test was performed to determine differences between two time points, however, none were significantly different.  
 
Supplementary Figure: Participant Flow Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screened for 
eligibility (n= 334) 
Eligible  
(n= 138) 
Declined (n= 58) 
Unable to cope or comply (n= 36) 
Time issues (n= 14) 
No reason given (n= 6) 
No trials/studies (n= 2) 
Baseline 
(n= 80) 
3 m 
 (n= 68) 
Excluded (n= 196) 
Palliative treatment (n= 76) 
Treatment started >1 week previously (n= 50) 
Recurrent disease (n= 16) 
Private patients (n= 15) 
Other (n= 39) 
Lost to follow-up (n= 6) 
Patient withdrawal-too ill/symptomatic (n= 3) 
Died (n= 2)  
Withdrawn- no radical treatment (n= 1) 
 
Died (n= 12) 
Lost to follow-up (n= 3) 
Patient withdrawal-too ill/symptomatic (n= 2) 
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